Saratov JOURNAL of Medical and Scientific Research

Pathomorphology of submacular hemorrhage (review)


Submacular hemorrhage is a serious complication of various eye diseases, leading to persistent and often irreversible loss of vision. Age-related macular degeneration (AMD) is one of the main causes of this pathology. The formed hemorrhage has pronounced destructive changes in the photoreceptor and inner nuclear layers of the retina. Patho-morphological disorders are mediated by the complex effect of neurotoxic blood breakdown products, traction effects of fibrin filaments, and blocking of metabolic processes between the retinal pigment epithelium and the overlying layers of the retina. The literature review was carried out using the search engines PubMed, Embase, Cochrane Library, the analysis of literature sources on a given topic, published from 1959 to 2020, was completed. The authors concluded that the study of morphological changes in the retina after acute submacular hemorrhage requires compliance with the principle of multimodal imaging, which makes it possible to establish prognostic criteria for the restoration of visual functions, as well as to facilitate the choice of surgical treatment tactics. This problem is poorly understood and requires additional clinical studies.

1. Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol 1997; (42): 195-213.
2. Bopp S. Subretinal hemorrhage. Natural course and staging. Ophthalmologe 2012; 109 (7): 635-43.
3. Kim JH, Chang YS, Kim JW, Kim CG. Characteristics of submacular hemorrhages in age-related macular degeneration. Optom Vis Sci 2017; (94): 556-63.
4. Wilkins CS, Mehta N, WuCY, etal. Outcomes of pars plana vitrectomy with subretinal tissue plasminogen activator injection and pneumatic displacement of fovea-involving submacular haemorrhage. BMJ Open Ophthalmol 2020; 5 (1): e000394.
5. Steel DH, Sandhu SS. Submacular hemorrhages associated with neovascular age-related macular degeneration. Br J Ophthalmol 2011; (95): 1051 -7.
6. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2 (2): e106-16.
7. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001; (108): 1893-901.
8. Gopinath B, Liew G, Burlutsky G, Mitchell P. Age-related macular degeneration and 5-year incidence of impaired activities of daily living. Maturitas 2014; (77): 263-6.
9. Gehrs K, Anderson D, Johnson L, Hageman G. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med 2006; (38): 450-71.
10. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001; (108): 697-704.
11. Green WR, Enger О Age-related macular degeneration histopathologic studies: The 1992 Lorenz E. Zimmerman lecture. Ophthalmology 1993; (100): 1519-35.
12. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; (146): 1029-39.
13. Kohn S, Nagy JA, Dvorak HF, et al. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor bloodvessels. Lab Invest 1992; (67): 596-607.
14. Berkow JW. Subretinal neovascularization in senile macular degeneration. Am J Ophthalmol 1984; (97): 143-7.
15. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol 1987; (31): 291-306.
16. Glatt H, Machemer R. Experimental Subretinal Hemorrhage in Rabbits. American Journal of Ophthalmology 1982; 94 (6): 762-73.
17. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol Vis Sci 2000; (41): 3158-64.
18. Ohno-Matsui К Molecular mechanism for choroidal neovascularization in age-related macular degeneration. Nippon Ganka Gakkai Zasshi 2003; 107 (11): 657-73.
19. Koshibu A. Ultrastructural studies on absorption of experimentally produced subretinal hemorrhage. I. Erythrophagocytosis at the early stage. Nippon Ganka Gakkai Zasshi 1978; (82): 428.
20. Koshibu A. Ultrastructural studies on absorption of experimentally produced subretinal hemorrhage. II. Autolysis of macrophages and disappearance of erythrocytes from the subretinal space at the late stage. Nippon Ganka Gakkai Zasshi 1978; (82): 471.
21. Koshibu A. Ultrastructural studies on absorption of experimentally produced subretinal hemorrhage. III. Absorption of erythrocyte breakdown products and retinal hemosiderosis at the late stage. Nippon Ganka Gakkai Zasshi 1979; (83): 386.
22. Johnson MW, Olsen KR, Hernandez E. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Retina 1991; (11): 250-8.
23. Wolter JR, Till GO. Multinucleated giant cells on Bruch's membrane late in recurrent retinal and subretinal hemorrhaging. Ophthalmologica 1989; (199): 53-9.
24. Cibis PA, Yamashita T. Experimental aspects of ocular siderosis and hemosiderosis. Am J Ophthalmol 1959; 8 (5) Pt2: 465-80.
25. Regnault FR. Vitreous hemorrhage. An experimental study. III. Experimental degeneration of the rabbit retina induced by hemoglobin injection into the vitreous. Arch Ophthalmol 1970; (83): 470.
26. Toth CA, Morse LS, Hjelmeland LM, Landers MB. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991; (109): 723-9.
27. Toth CA, Benner JD, Hjelmeland LM, et al. Ultramicrosurgical removal of subretinal hemorrhage in cats. Am J Ophthalmol 1992; (113): 175-82.
28. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retinal Eye Res 2016; (50): 1-24.
29. ScupolaA, CoscasG, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 1999; (213): 9-102.
30. Papavasileiou E, Steel DH, Liazos E, et al. Intravitreal tissue plasminogen activator, perfluoropropane (c3f8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration. Retina 2013; (33): 846e53.
31. Bennett SR, Blodi CF, Folk JO Factors prognostic of visual outcome in patients with subretinal hemorrhage involving the fovea. Am J Ophthalmol 1990; (109): 33-7.
32. Avery RL, Fekrat S, Hawkins BS, et al. Natural history of sub foveal hemorrhage in age-related macular degeneration. Retina 1996; (16): 183-9.
33. Stanescu-Segall D, Balta F, Jackson TL. Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature. Surv Ophthalmol 2016; 61 (1): 18-32.
34. Fine HF, Iranmanesh R, Del Priore LV, et al. Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration. Retina 2010; (30): 1588e94.
35. Sacu S, Stifter E, Vecsei-Marlovits PV, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye (Lond) 2009; (23): 1404e10.
36. Jung JH, Lee JK, Lee JE, Oum BS. Results of vitrectomy for breakthrough vitreous hemorrhage associated with age-related macular degeneration and polypoidal choroidal vasculopathy. Retina 2010; (30): 865-73.
37. Hasegawa T, Otani A, Sasahara M, et al. Prognostic factors of vitreous hemorrhage secondary to exudative age-related macular degeneration. Am J Ophthalmol 2010; (149): 322-9. e1.
38. Altaweel MM, Daniel E, Martin DF, et al. Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology 2015; 122 (2): 391-8. e5.
39. Karagiannis D, Chatziralli I, Kaprinis K, et al. Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration. Clin Interv Aging 2017; 12 (3): 1829-33.
40. KurodaY, Yamashiro K, Miyake M, etal. Factors associated with recurrence of age-related macular degeneration after Anti-Vascular Endothelial Growth Factor Treatment: a retrospective cohort study. Ophthalmology 2015; 122 (11): 2303-10.
41. Reichel E, Duker JS, Puliafito CA. Indocyanine green angiography and choroidal neovascularization obscured by hemorrhage. Ophthalmology 1995; (102): 1871-6.
42. Kramer M, Mimouni K, Priel E, et al. Comparison of fluorescein angiography and indocyanine green angiography for imaging of choroidal neovascularization in hemorrhagic age-related macular degeneration. Am J Ophthalmol 2000; 129 (4): 495-500.
43. Kim JH, Chang YS, Kim JW, et al. Prevalence of subtypes of reticularpseudodrusen in newly diagnosed exudative age-related macular degeneration and polypoidal choroidal vasculopathy in Korean patients. Retina 2015; (35): 2604-12.
44. Ueda-Arakawa N, Tsujikawa A, Yamashiro K, et al. Visual prognosis of eyes with submacular hemorrhage associated with exudative age-related macular degeneration. Japanese Journal of Ophthalmology 2012; 56 (6): 589-98.
45. Marmor MF. Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 1999; (97): 239-49.
46. Schutze C, Wedl M, Baumann B, et al. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol 2015; (159): 1100-14.
47. Schutze C, Teleky K, Baumann B, et al. Polarisation-sensitive ОСТ is useful for evaluating retinal pigment epithelial lesions in patients with neovascular AMD. Br J Ophthalmol 2016; (100): 371-7.

2021_01_028-032.pdf335.64 KB

No votes yet